Analysts have raised Bayer's fair value estimate to €54.92 per share from €34.97, reflecting a reassessment of litigation risk and pipeline prospects. Deutsche Bank upgraded the stock to Buy and lifted its price target to €60 from €45 following a Supreme Court ruling on glyphosate liability, while DZ Bank moved to Buy with a €51 target. Jefferies assumed coverage at Hold but raised its target to €40 from €25, and Goldman Sachs removed Bayer from its European Conviction List. The updated valuation incorporates a long-term annual revenue growth assumption of 2.39%, a target net profit margin of 7.31%, a future P/E multiple of 17.73x, and a discount rate of 5.26%.
Deutsche Bank Aktiengesellschaft
Goldman Sachs Group Inc
Jefferies Financial Group Inc
Bayer AG NA